Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Sell
18
TBIO Quote, Financials, Valuation and Earnings
Last price:
$0.42
Seasonality move
:
28.46%
Day range:
$0.38 - $0.48
52-week range:
$0.35 - $15.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
--
Volume:
10.2K
Avg. volume:
6K
1-year change:
-93.93%
Market cap:
$753.4K
Revenue:
$27.5M
EPS (TTM):
-$30.78
Analysts' Opinion
-
Consensus RatingTelesis Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Telesis Bio has an estimated upside of 16843.16% from its current price of $0.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.43.
Fair Value
-
According to the consensus of 1 analyst, Telesis Bio has 16843.16% upside to fair value with a price target of -- per share.
TBIO vs. S&P 500
-
Over the past 5 trading days, Telesis Bio has underperformed the S&P 500 by -24.62% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Telesis Bio does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Telesis Bio revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Telesis Bio reported revenues of $1.6M.
Earnings Growth
-
Telesis Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Telesis Bio reported earnings per share of -$7.62.
Enterprise value:
26.3M
EV / Invested capital:
--
Price / LTM sales:
0.04x
EV / EBIT:
--
EV / Revenue:
1.50x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.4M
Return On Assets:
-61.01%
Net Income Margin (TTM):
-282.59%
Return On Equity:
-151.32%
Return On Invested Capital:
-112.74%
Operating Margin:
-675.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | $17.2M | $29.5M | $17.5M | $7M | $1.6M | |
| Gross Profit | $7.5M | $18.6M | $8.4M | $5M | -$799K | |
| Operating Income | -$48.9M | -$37.5M | -$35.2M | -$7.4M | -$10.5M | |
| EBITDA | -$46.9M | -$33.4M | -$41M | -$6.6M | -$10.5M | |
| Diluted EPS | -$30.89 | -$24.45 | -$30.78 | -$5.10 | -$7.62 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $127.3M | $72M | $61.5M | $15.2M | |
| Total Assets | -- | $136.4M | $97.3M | $114.5M | $52.7M | |
| Current Liabilities | -- | $6.8M | $18.2M | $10.4M | $8M | |
| Total Liabilities | -- | $24M | $32.6M | $58.5M | $42.8M | |
| Total Equity | -- | $112.4M | $64.7M | $56.1M | $9.9M | |
| Total Debt | -- | $14.5M | $14.9M | $19.9M | $5.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$43.1M | -$42.2M | -$21.8M | -$10.3M | -$5.3M | |
| Cash From Investing | -$57.8M | $35.9M | -$3.3M | $6.8M | $1.1M | |
| Cash From Financing | -$611K | $30.8M | -$15.2M | $26.7M | -$7K | |
| Free Cash Flow | -$48.1M | -$44.9M | -$22.8M | -$11.4M | -$5.4M | |
TBIO
Sector
Market Cap
$753.4K
$45.9M
Price % of 52-Week High
2.75%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-93.93%
-32.15%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.49
200-day SMA
Sell
Level
$3.70
Bollinger Bands (100)
Sell
Level
0.81 - 3.31
Chaikin Money Flow
Sell
Level
-51.5M
20-day SMA
Sell
Level
$0.54
Relative Strength Index (RSI14)
Sell
Level
36.59
ADX Line
Sell
Level
25.42
Williams %R
Neutral
Level
-77.0718
50-day SMA
Sell
Level
$1.01
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
84.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.9258)
Sell
CA Score
(Annual)
Level (-2.9659)
Buy
Beneish M-Score
(Annual)
Level (-3.2758)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.2591)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents and BioXp biofoundry services.
Stock Forecast FAQ
In the current month, TBIO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TBIO average analyst price target in the past 3 months is --.
-
Where Will Telesis Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Telesis Bio share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Telesis Bio?
Analysts are divided on their view about Telesis Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Telesis Bio is a Sell and believe this share price will drop from its current level to --.
-
What Is Telesis Bio's Price Target?
The price target for Telesis Bio over the next 1-year time period is forecast to be -- according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Telesis Bio is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of TBIO?
You can purchase shares of Telesis Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Telesis Bio shares.
-
What Is The Telesis Bio Share Price Today?
Telesis Bio was last trading at $0.42 per share. This represents the most recent stock quote for Telesis Bio. Yesterday, Telesis Bio closed at $0.43 per share.
-
How To Buy Telesis Bio Stock Online?
In order to purchase Telesis Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
